Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .
Sleep and cognition at baseline and the effects of REM sleep diminution after 1 week of antidepressive treatment in patients with depression.
It has been hypothesized that non-rapid eye movement ( NREM ) sleep facilitates declarative memory consolidation , and rapid eye movement ( REM ) sleep is particularly important in promoting procedural learning . The aim of this study was to examine the effects of pharmacological REM sleep suppression on performance in different neuropsychological tasks . For our baseline , we chose 41 moderately depressed patients ( age range 19 - 44 years ) , who were not taking antidepressants .  In the morning after polysomnography , we tested memory recall and cognitive flexibility by assessment of verbal and figural fluency , a shift of attention task and the Trail Making Test B. After recording baseline values , patients were assigned r and omly to one of three treatment groups : medication with citalopram ; medication with reboxetine ; or exclusive treatment with psychotherapy . Retesting took place 1 week after onset of treatment . The main results were : ( 1 ) an association of slow-wave sleep with verbal memory performance at baseline ; ( 2 ) a suppression of REM sleep in patients taking citalopram and reboxetine ; ( 3 ) no differences regarding neuropsychological performance within the treatment groups ; and ( 4 ) no association of REM sleep diminution with decreases in memory performance or cognitive flexibility in patients treated with citalopram or reboxetine . In line with other studies , our results suggest that there are no negative effects of a decrease in REM sleep on memory performance in patients taking antidepressants
Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .